Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

This trial is testing TQB2868 (a new immunotherapy drug) combined with anlotinib (a targeted anti-cancer drug) and chemotherapy as a first-line treatment for metastatic pancreatic cancer. Pancreatic cancer is notoriously difficult to treat, and this study is exploring whether this three-drug combination can improve outcomes. **You may be eligible if...** - You have been diagnosed with pancreatic ductal adenocarcinoma confirmed by biopsy or fine needle aspiration - Your cancer has spread (metastatic) with at least one measurable lesion - You have not received prior systemic treatment for metastatic pancreatic cancer (prior neoadjuvant or adjuvant therapy is okay if finished more than 6 months ago) - You are between 18 and 75 years old with good performance status (ECOG 0 or 1) - Your major organ functions (liver, kidneys, heart) are adequate **You may NOT be eligible if...** - You have already received chemotherapy or targeted therapy for metastatic disease - You have active brain metastases - You have a serious autoimmune condition or are on immunosuppressive medications - You have uncontrolled infections or other serious health conditions Talk to your doctor to see if this trial is right for you.